Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AUPH Aurinia Pharmaceuticals

Market Closed 09-18 16:00:00 EDT

16.90

-0.06

-0.35%

盘后16.90

+0.000.00%

19:43 EDT

High17.03	Low16.80	Vol1.20M
Open16.93	D1 Closing16.96	Amplitude1.36%
Mkt Cap2.25B	Tradable Cap2.18B	Total Shares133.05M
T/O20.26M	T/O Rate0.93%	Tradable Shares129.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AUPH","market":"US","secType":"STK","nameCN":"Aurinia Pharmaceuticals","latestPrice":16.9,"timestamp":1789761600000,"preClose":16.96,"halted":0,"volume":1198256,"hourTrading":{"tag":"盘后","latestPrice":16.9,"preClose":16.9,"latestTime":"19:43 EDT","volume":185377,"amount":3132875.9639,"timestamp":1789775031168,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.003537735849056738,"floatShares":129000000,"shares":133051168,"eps":2.303212,"marketStatus":"Market Closed","change":-0.06,"latestTime":"09-18 16:00:00 EDT","open":16.93,"high":17.03,"low":16.8,"amount":20255947.310144,"amplitude":0.013561,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.303212,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":951454800000,"exchange":"NASDAQ","adjPreClose":16.96,"preHourTrading":{"tag":"盘前","latestPrice":16.8509,"preClose":16.96,"latestTime":"09:25 EDT","volume":2253,"amount":37716.182031000004,"timestamp":1789737904658,"change":-0.1091,"changeRate":-0.006433,"amplitude":0.018001},"postHourTrading":{"tag":"盘后","latestPrice":16.9,"preClose":16.9,"latestTime":"19:43 EDT","volume":185377,"amount":3132875.9639,"timestamp":1789775031168,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.3424775586981006,"impliedVol":0.3223,"impliedVolPercentile":0.0677},"requestUrl":"/m/hq/s/AUPH/wiki","defaultTab":"wiki","newsList":[{"id":"2665526983","title":"13D Filings","url":"https://stock-news.laohu8.com/highlight/detail?id=2665526983","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665526983?lang=en_us&edition=fundamental","pubTime":"2026-09-05 06:59","pubTimestamp":1788562740,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBCH","BK4170","GNK","BK4097","AUPH","ALLT","IMTX","BK4021","BK4139","BDRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664874706","title":"LB Pharmaceuticals Names Joseph Miller CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2664874706","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664874706?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:38","pubTimestamp":1788439125,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals (LBRX) said Thursday it named Joseph Miller its chief financial officer.Miller was previously Aurinia Pharmaceuticals' (AUPH) CFO, LB Pharmaceuticals said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MLR","CFO","BK4149","AUPH","BK4139","BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662518757","title":"Aurinia Pharmaceuticals (AUPH) Is Up 8.4% After Teva Agrees To Delay Generic Voclosporin Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2662518757","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662518757?lang=en_us&edition=fundamental","pubTime":"2026-08-26 05:23","pubTimestamp":1787693035,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals recently entered into a settlement with Teva Pharmaceuticals resolving U.S. patent litigation over Teva’s proposed generic 7.9 mg voclosporin capsules, with Teva agreeing that Aurinia’s patents, expiring in December 2037, are valid, enforceable, and would be infringed by U.S. sales of its generic.\nThe agreement, which restricts Teva from launching its generic voclosporin in the U.S. before December 7, 2036 (subject to contingencies and FDA approval), materially...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-pharmaceuticals-auph-is-up-84-after-teva-agrees-to-d","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-pharmaceuticals-auph-is-up-84-after-teva-agrees-to-d","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661181842","title":"Aurinia Pharmaceuticals (AUPH) After The Teva Settlement Is The Stock A Bargain","url":"https://stock-news.laohu8.com/highlight/detail?id=2661181842","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661181842?lang=en_us&edition=fundamental","pubTime":"2026-08-22 05:23","pubTimestamp":1787347392,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) recently reached a settlement with Teva Pharmaceuticals over U.S. patents covering voclosporin capsules, setting December 7, 2036 as the earliest launch date for Teva’s potential generic, subject to FDA approval.\nSee our latest analysis for Aurinia Pharmaceuticals.\nThe settlement news appears to have aligned with a strong run in Aurinia Pharmaceuticals' shares, with a 7 day share price return of 13.77% and a year to date share price return of 12.51% at a last...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-pharmaceuticals-auph-after-the-teva-settlement-is-th","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-pharmaceuticals-auph-after-the-teva-settlement-is-th","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660941235","title":"Aurinia Shares Gains After Settling Patent Lawsuit with Teva","url":"https://stock-news.laohu8.com/highlight/detail?id=2660941235","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660941235?lang=en_us&edition=fundamental","pubTime":"2026-08-20 23:51","pubTimestamp":1787241060,"startTime":"0","endTime":"0","summary":"Shares of Aurinia Pharmaceuticals rose after the company entered a settlement agreement with Teva Pharmaceuticals to resolve a patent infringement lawsuit it filed against Teva.The stock gained 6.2% t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660856283","title":"Aurinia Pharmaceuticals (AUPH) Gets a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2660856283","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660856283?lang=en_us&edition=fundamental","pubTime":"2026-08-20 17:45","pubTimestamp":1787219135,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Stacy Ku from TD Cowen maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $17.00. The compa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/aurinia-pharmaceuticals-auph-gets-a-buy-from-td-cowen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/aurinia-pharmaceuticals-auph-gets-a-buy-from-td-cowen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","COWN","TD","BK4139","BK4207","BK4585","BK4566","AUPH","GSIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660532473","title":"Aurinia settles patent litigation with Teva","url":"https://stock-news.laohu8.com/highlight/detail?id=2660532473","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660532473?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:11","pubTimestamp":1787170262,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) announced that it and its subsidiary, Aurinia Pharma U.S., Inc., have entered into a settlement agreement with Teva ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aurinia-settles-patent-litigation-with-teva-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aurinia-settles-patent-litigation-with-teva-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BBP","BK4139","AUPH","NXTI","RND","USRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660478718","title":"Aurinia Settles Teva Patent Suit, Bars Generic Voclosporin Launch Until Dec. 7, 2036","url":"https://stock-news.laohu8.com/highlight/detail?id=2660478718","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660478718?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:06","pubTimestamp":1787169960,"startTime":"0","endTime":"0","summary":"Aurinia settles Teva patent suit, bars generic voclosporin launch until Dec. 7, 2036Aurinia Pharmaceuticals settled patent litigation with Teva over a proposed U.S. generic voclosporin 7.9 mg capsule.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL8jKD3C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660787834","title":"Aurinia Pharmaceuticals - Teva May Launch Generic Voclosporin in U.S. no Earlier than December 7, 2036","url":"https://stock-news.laohu8.com/highlight/detail?id=2660787834","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660787834?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:05","pubTimestamp":1787169900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nTUA3FZZ8R:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660478793","title":"Aurinia Pharmaceuticals - Continues Patent Litigation Against Multiple Generic Companies in New Jersey","url":"https://stock-news.laohu8.com/highlight/detail?id=2660478793","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660478793?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:05","pubTimestamp":1787169900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nTUA3FZZ8R:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660478204","title":"Aurinia Settles Patent Litigation with Teva","url":"https://stock-news.laohu8.com/highlight/detail?id=2660478204","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660478204?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:05","pubTimestamp":1787169900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nTUA3FZZ8R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660492294","title":"CannaPharmaRx Q2 FY26 Net Loss Widens to USD 1.91 Million; Revenue Rises 19.26% to USD 276,218","url":"https://stock-news.laohu8.com/highlight/detail?id=2660492294","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660492294?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:51","pubTimestamp":1787086316,"startTime":"0","endTime":"0","summary":"CannaPharmaRx Q2 FY26 net loss widens to USD 1.91 million; revenue rises 19.26% to USD 276,218CannaPharmaRx posted Q2 revenue of USD 276,218, up 19.26% year over year; net loss widened to USD 1.91 mil","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL8z4Ggs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","AUPH","CPMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657623663","title":"Aurinia Pharmaceuticals is Maintained at Sector Perform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2657623663","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657623663?lang=en_us&edition=fundamental","pubTime":"2026-08-08 02:42","pubTimestamp":1786128120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AUPH/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSIB","LU0310800379.SGD","BK4207","BK4139","LU0708994859.HKD","LU1267930573.SGD","AUPH","LU0128525929.USD","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657643277","title":"RBC Adjusts PT on Aurinia Pharmaceuticals to $16 From $15, Keeps Sector Perform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657643277","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657643277?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:13","pubTimestamp":1786104796,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) has an average rating of overweight and mean price target of $17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657655546","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: VistaGen Therapeutics (VTGN), Iovance Biotherapeutics (IOVA) and Aurinia Pharmaceuticals (AUPH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657655546","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657655546?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:50","pubTimestamp":1786031409,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on VistaGen Therapeutics (VTGN), Iovance Biotherapeut...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-vistagen-therapeutics-vtgn-iovance-biotherapeutics-iova-and-aurinia-pharmaceuticals-auph-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-vistagen-therapeutics-vtgn-iovance-biotherapeutics-iova-and-aurinia-pharmaceuticals-auph-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","HCSG","LU0128526141.USD","BK4581","IOVA","BK4588","BK4139","LABU","LU0029874061.USD","XLV","VTGN","BK4585","BK4137","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657631916","title":"Aurinia Pharmaceuticals Q2 EPS $0.28 Beats $0.24 Estimate, Sales $83.220M Beat $79.357M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657631916","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657631916?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:40","pubTimestamp":1786020010,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.24 by 16.67 percent. This is a 75 percent increase over earnings of $0.16 per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60993751/aurinia-pharmaceuticals-q2-eps-0-28-beats-0-24-estimate-sales-83-220m-beat-79-357m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657363970","title":"Aurinia Publishes Corporate Presentation Outlining Lupkynis Growth Strategy, Aritinercept Development Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2657363970","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657363970?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:28","pubTimestamp":1786019299,"startTime":"0","endTime":"0","summary":"Aurinia publishes corporate presentation outlining LUPKYNIS growth strategy, aritinercept development plansAurinia highlighted continued commercial growth for lupus nephritis drug LUPKYNIS.Six months ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL1DwvK4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657508639","title":"Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657508639","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657508639?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:13","pubTimestamp":1786018400,"startTime":"0","endTime":"0","summary":"Aug 06 (Reuters) - Aurinia Pharmaceuticals Q2 product revenue USD 79.412 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 06-AUG-202612:01:01.21 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nRSD1NGB8m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657639447","title":"Aurinia Pharmaceuticals sees FY26 revenue $315M-$325M, consensus $325.82M","url":"https://stock-news.laohu8.com/highlight/detail?id=2657639447","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657639447?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:12","pubTimestamp":1786018368,"startTime":"0","endTime":"0","summary":"Aurinia reiterates its guidance for 2026 total revenue of $315M-$325M, up 11% to 15% compared to 2025, and 2026 net product sales of $305M-$315M, u...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aurinia-pharmaceuticals-sees-fy26-revenue-315m-325m-consensus-325-82m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aurinia-pharmaceuticals-sees-fy26-revenue-315m-325m-consensus-325-82m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657639898","title":"Aurinia Q2 Net Income Climbs 74% to $37.4 Million; Revenue Rises 19% to $83.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657639898","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657639898?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:08","pubTimestamp":1786018099,"startTime":"0","endTime":"0","summary":"Aurinia Q2 net income climbs 74% to $37.4 million; revenue rises 19% to $83.2 millionAurinia Pharmaceuticals posted Q2 revenue of USD 83.2 million, up 19% from a year earlier.Net income climbed 74% to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL3lbW84:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.auriniapharma.com","stockEarnings":[{"period":"1week","weight":0.0497},{"period":"1month","weight":0.0451},{"period":"3month","weight":0.0267},{"period":"6month","weight":0.2054},{"period":"1year","weight":0.3111},{"period":"ytd","weight":0.0596}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0096},{"period":"3month","weight":0.02},{"period":"6month","weight":0.1744},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.117}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.071692},{"month":2,"riseRate":0.416667,"avgChangeRate":0.005745},{"month":3,"riseRate":0.5,"avgChangeRate":0.089864},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.004824},{"month":5,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":6,"riseRate":0.5,"avgChangeRate":-0.009565},{"month":7,"riseRate":0.583333,"avgChangeRate":0.027825},{"month":8,"riseRate":0.583333,"avgChangeRate":-0.006441},{"month":9,"riseRate":0.5,"avgChangeRate":0.062602},{"month":10,"riseRate":0.583333,"avgChangeRate":0.048963},{"month":11,"riseRate":0.583333,"avgChangeRate":0.036405},{"month":12,"riseRate":0.416667,"avgChangeRate":0.092842}],"exchange":"NASDAQ","name":"Aurinia Pharmaceuticals","nameEN":"Aurinia Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aurinia Pharmaceuticals(AUPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aurinia Pharmaceuticals,AUPH,Aurinia Pharmaceuticals股票,Aurinia Pharmaceuticals股票老虎,Aurinia Pharmaceuticals股票老虎国际,Aurinia Pharmaceuticals行情,Aurinia Pharmaceuticals股票行情,Aurinia Pharmaceuticals股价,Aurinia Pharmaceuticals股市,Aurinia Pharmaceuticals股票价格,Aurinia Pharmaceuticals股票交易,Aurinia Pharmaceuticals股票购买,Aurinia Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aurinia Pharmaceuticals(AUPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction